BTIG Reaffirms Their Hold Rating on LivaNova PLC (LIVN)

BTIG analyst Sean Lavin reiterated a Hold rating on LivaNova PLC (LIVN) yesterday. The company’s shares opened today at $93.79.

Lavin commented:

“Last week, LIVN reported Q4 results and presented FY19 guidance during our annual Snowbird conference. Q4 top-line results were encouraging with solid Cardiopulmonary and Neuromod sales and the sizable TandemLife sequential ramp offsetting weak Perceval results. For FY19, although management expects a ~1% top-line contribution from VNS in Depression treatment, trial expenses and related infrastructure build-up will depress EPS by $0.15-0.20. We think the magnitude of the expense ramp to lay the groundwork for this new vertical shouldn’t be surprising though we recognize it’s a bit of a reality check for more bullish expectations around TRD. Even so, the FY19 and FY20 revenue contribution from Depression are better than we would have thought and the outlook for the underlying business of 4-6% is consistent with our general thinking.”

According to TipRanks.com, Lavin is a 5-star analyst with an average return of 11.0% and a 60.6% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.

LivaNova PLC has an analyst consensus of Strong Buy, with a price target consensus of $131.75.

See today’s analyst top recommended stocks >>

Based on LivaNova PLC’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $297 million and GAAP net loss of $211 million. In comparison, last year the company had a GAAP net loss of $112 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the Cardiac Surgery and Neuromodulation, and Other Corporate segments.